Eutropics Pharmaceuticals to Present Data on Personalized Diagnostic for AML Patient Management at American Society of Clinical Oncology 2013

Published: May 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Eutropics Pharmaceuticals Inc. announced today that Eutropics and The University of Texas MD Anderson Cancer Center will present results from a clinical study employing Eutropics’ proprietary PraediCare Dx (BH3 profiling) assay to discriminate therapeutic response in acute myeloid leukemia (AML) patients to standard-of-care-based chemotherapy.

Help employers find you! Check out all the jobs and post your resume.

Back to news